• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down 2%; Home Depot Posts Upbeat Earnings

    8/15/23 12:00:12 PM ET
    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DCTH alert in real time by email

    U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 90 points on Tuesday.

    The Dow traded down 0.75% to 35,042.16 while the NASDAQ fell 0.66% to 13,697.15. The S&P 500, also fell, dropping, 0.76% to 4,455.45.

    Check This Out: LyondellBasell, Dropbox And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

    Health care shares fell by just 0.1% on Tuesday.

    In trading on Tuesday, energy shares dipped by 1.9%.

     

    Top Headline

    The Home Depot, Inc. (NYSE:HD) reported better-than-expected results for its second quarter.

    The company posted a second-quarter FY23 sales decline of 2% year-on-year to $42.92 billion, beating the analyst consensus of $42.25 billion. EPS of $4.65 beat the analyst consensus of $4.46.

    The board of directors also authorized a new $15 billion share repurchase program effective August 15, 2023, replacing its previous authorization.

     

    Equities Trading UP

    Delcath Systems, Inc. (NASDAQ:DCTH) shares shot up 115% to $6.71 after the company announced FDA approval of HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.

    Shares of Novo Integrated Sciences, Inc. (NASDAQ:NVOS) got a boost, shooting 56% to $0.1106 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.

    Siyata Mobile Inc. (NASDAQ:SYTA) shares were also up, gaining 33% to $4.4001 following upbeat quarterly sales.

     

    Equities Trading DOWN

    F45 Training Holdings Inc. (NYSE:FXLV) shares dropped 76% to $0.1757 after the company announced it intends to voluntarily delist and deregister its securities.

    Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) were down 69% to $2.2798 after the company reported initial results from its Phase 1 multiple-ascending dose study of DT-216 for the treatment of Friedrich ataxia. The company said there were injection site reactions.

    Galecto, Inc. (NASDAQ:GLTO) was down, falling 69% to $0.72 after the company announced topline results from its Phase 2b GALACTIC-1 trial of GB0139 for idiopathic pulmonary fibrosis, which showed the trial did not meet its primary endpoint. The company plans to discontinue development of GB0139.

    Also Check This Out: Top 5 Tech And Telecom Stocks You May Want To Dump In August

     

    Commodities

    In commodity news, oil traded down 2.1% to $80.80 while gold traded down 0.1% at $1,942.00.

    Silver traded up 0.1% to $22.73 on Tuesday while copper fell 1.3% to $3.6760.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 fell 1.12%, London’s FTSE 100 fell 1.76% while Spain’s IBEX 35 Index fell 1.18% The German DAX fell 1.06% French CAC 40 fell 1.33%

    The ZEW Indicator of Economic Sentiment for Germany rose to -12.3 in August from -14.7 in July.

    The unemployment rate in the UK rose to 4.2% during the three months to June 2023, recording the highest level since late-2021. Average weekly earnings, including bonuses in the UK, increased by 8.2% year-over-year to GBP 663/week in the three months to June. Labor productivity in the UK rose 0.7% on quarter in the three months to June.

     

    Asia Pacific Markets

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 gaining 0.56%, China’s Shanghai Composite Index falling 0.07% and Hong Kong’s Hang Seng Index falling 1.03%. India’s S&P BSE Sensex, meanwhile, rose 0.12%.

    The People’s Bank of China cut the one-year medium-term lending facility rates by 15 bps on August 15th. China's retail sales rose by 2.5% year-over-year in July, slowing from a 3.1% increase in the previous month. The country’s industrial production rose 3.7% year-over-year in July, slowing from a 4.4% growth in June

    Industrial production in Japan rose by 2.4 percent month-over-month in June. The Japanese economy expanded by 6.0% on an annualized basis in the second quarter, higher than the revised 3.7% growth in the previous period.

     

    Economics

    Retail sales in the U.S. rose 0.7% month-over-month in July, beating market expectations for a 0.4% growth.

    Export prices in the U.S. rose 0.7 percent month-over-month in July, while import prices increased 0.4% month-over-month in July.

    The NY Empire State Manufacturing Index fell to -19 in August from 1.1 in July, and down from market estimates of -1.

    The NAHB/Wells Fargo Housing Market Index declined to 50 in August from 56 in July.

    Total business inventories came in unchanged for June.

    Now Read This: NVIDIA To Rally More Than 23%? Here Are 10 Other Analyst Forecasts For Tuesday

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,736,010 cases with around 1,172,110 deaths. India confirmed a total of at least 44,996,310 cases and 531,920 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 693,580,690 cases of COVID-19 worldwide with more than 6,907,930 deaths.

    Get the next $DCTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DCTH
    $DSGN
    $FXLV
    $GLTO

    CompanyDatePrice TargetRatingAnalyst
    Design Therapeutics Inc.
    $DSGN
    1/7/2026$18.00Outperform
    Oppenheimer
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Home Depot Inc.
    $HD
    12/10/2025$430.00 → $410.00Outperform
    Telsey Advisory Group
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$14.00Market Perform → Outperform
    Leerink Partners
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$15.00Buy
    Craig Hallum
    Galecto Inc.
    $GLTO
    12/1/2025$32.00Buy
    Guggenheim
    Design Therapeutics Inc.
    $DSGN
    11/20/2025$13.00Sector Perform → Outperform
    RBC Capital Mkts
    Home Depot Inc.
    $HD
    11/19/2025$455.00 → $430.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Galecto Inc.

    SCHEDULE 13D/A - Galecto, Inc. (0001800315) (Subject)

    2/11/26 6:11:02 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Galecto Inc.

    8-K - Galecto, Inc. (0001800315) (Filer)

    2/11/26 5:10:21 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Galecto Inc.

    424B5 - Galecto, Inc. (0001800315) (Filer)

    2/11/26 5:02:46 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bruno Julianne converted options into 129,000 shares, increasing direct ownership by 1,606% to 137,032 units (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    2/12/26 6:05:08 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fairmount Funds Management Llc converted options into 8,713,000 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    2/12/26 6:03:41 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP - Human Resources Smith Stephanie

    4 - HOME DEPOT, INC. (0000354950) (Issuer)

    2/3/26 5:11:25 PM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galecto Announces Pricing of $275 Million Underwritten Public Offering

    BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expec

    2/10/26 10:42:03 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

    BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series C preferred stock will be convertible into 1,000 shares of common stock at

    2/10/26 4:04:47 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Home Depot to Host Fourth Quarter & Fiscal Year Earnings Conference Call on February 24

    ATLANTA, Feb. 10, 2026 /PRNewswire/ -- The Home Depot®, the world's largest home improvement retailer, announced today that it will hold its Fourth Quarter & Fiscal Year Earnings Conference Call on Tuesday, February 24, at 9 a.m. ET. A webcast will be available by logging onto http://ir.homedepot.com/events-and-presentations and selecting the Fourth Quarter Earnings Conference Call icon or directly at https://event.choruscall.com/mediaframe/webcast.html?webcastid=hLub2smn. The webcast will be archived, and the replay will be available beginning at approximately noon on Februar

    2/10/26 8:00:00 AM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sylvester John Richard bought $38,992 worth of shares (4,386 units at $8.89), increasing direct ownership by 42% to 14,936 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/25/25 4:15:07 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $98,049 worth of shares (11,500 units at $8.53), increasing direct ownership by 4% to 330,834 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/13/25 11:53:28 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Director Brenneman Gregory D bought $999,767 worth of $.05 Common Stock (2,884 units at $346.66) (SEC Form 4)

    4 - HOME DEPOT, INC. (0000354950) (Issuer)

    3/18/25 4:35:09 PM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Design Therapeutics with a new price target

    Oppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00

    1/7/26 9:09:56 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telsey Advisory Group reiterated coverage on Home Depot with a new price target

    Telsey Advisory Group reiterated coverage of Home Depot with a rating of Outperform and set a new price target of $410.00 from $430.00 previously

    12/10/25 8:00:40 AM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Financials

    Live finance-specific insights

    View All

    The Home Depot to Host Fourth Quarter & Fiscal Year Earnings Conference Call on February 24

    ATLANTA, Feb. 10, 2026 /PRNewswire/ -- The Home Depot®, the world's largest home improvement retailer, announced today that it will hold its Fourth Quarter & Fiscal Year Earnings Conference Call on Tuesday, February 24, at 9 a.m. ET. A webcast will be available by logging onto http://ir.homedepot.com/events-and-presentations and selecting the Fourth Quarter Earnings Conference Call icon or directly at https://event.choruscall.com/mediaframe/webcast.html?webcastid=hLub2smn. The webcast will be archived, and the replay will be available beginning at approximately noon on Februar

    2/10/26 8:00:00 AM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    The Home Depot Provides a Strategic Update; Reaffirms Fiscal 2025 Guidance; Establishes a Preliminary Fiscal 2026 Outlook and a Market Recovery Case

    ATLANTA, Dec. 9, 2025 /PRNewswire/ -- The Home Depot®, the world's largest home improvement retailer, will discuss key strategic priorities, provide a preliminary 2026 outlook and a market recovery case, today at its 2025 Investor and Analyst Conference.  Today's conference will begin at 8:30 a.m. ET and will be available in its entirety through a live webcast and replay at ir.homedepot.com/events-and-presentations. During today's conference, the company will discuss how it is uniquely positioned to grow market share and deliver shareholder value through its strategy to: drive

    12/9/25 6:00:00 AM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    The Home Depot Declares Quarterly Dividend of $2.30

    ATLANTA, Nov. 20, 2025 /PRNewswire/ -- The Home Depot®, the world's largest home improvement retailer, today announced that its board of directors declared a quarterly cash dividend of $2.30 per share. The dividend is payable on December 18, 2025, to shareholders of record at the close of business on December 4, 2025. This is the 155th consecutive quarter the company has paid a cash dividend. The Home Depot is the world's largest home improvement specialty retailer.  At the end of the third quarter, the company operated a total of 2,356 retail stores and over 1,200 SRS locatio

    11/20/25 4:10:00 PM ET
    $HD
    RETAIL: Building Materials
    Consumer Discretionary

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications

    $DCTH
    $DSGN
    $FXLV
    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mirion Technologies Set to Join S&P SmallCap 600

    NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Mirion Technologies Inc. (NYSE:MIR) will replace GMS Inc. (NYSE:GMS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 9. S&P 500 and 100 constituent Home Depot Inc. (NYSE:HD) acquired GMS in a deal that was completed today. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 9, 2025 S&P SmallCap 600 Addition Mirion Technologies MIR Information Technology September 9, 2025 S&P SmallCap 600 Deletion GMS GMS Industrials For more information about S&P Dow Jones Indices, please visit www

    9/4/25 5:28:00 PM ET
    $GMS
    $HD
    $MIR
    RETAIL: Building Materials
    Consumer Discretionary
    Industrial Machinery/Components
    Industrials